Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1641 1677 1678 1794
This examiner grants 65% of resolved cases
Shafiqul Haq serves in Tech Center 1700 and Art Unit 1641. He has 944 resolved cases with an allowance rate of 64.8%. This rate indicates a moderate level of grant activity. The median days to allowance is 1287, which provides a benchmark for the expected duration of the patent prosecution process.
The interview lift for Haq is 55.2%. This increase is substantial, suggesting that interviews are an extremely powerful tool for securing an allowance with this examiner. With 944 resolved cases, this trend is highly reliable. The 1287-day median to allowance reflects the time investment required for successful applications in Tech Center 1700.
In Art Unit 1641, Haq's 64.8% allowance rate and 55.2% interview lift are the most important metrics for practitioners. The 944 resolved cases demonstrate a clear benefit to direct engagement. Applicants should use the 1287-day figure to manage expectations while prioritizing interviews to leverage the lift.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18130874 | SELF-HEALABLE CHEMICAL DETECTING SENSOR EMBEDDING TRANSITION METAL-ADSORBED PAA-PVA-BORAX FIBER-GEL | Final Rejection | UIF (University Industry Foundation), Yonsei University |
| 18620441 | PROCESS FOR PURIFICATION OF PROTEIN | Non-Final OA | Kashiv BioSciences, LLC |
| 18620649 | PROCESS FOR PURIFICATION OF PROTEIN | Final Rejection | Kashiv BioSciences, LLC |
| 18766065 | LATERAL FLOW METHODS, ASSAYS, AND DEVICES FOR DETECTING THE PRESENCE OR MEASURING THE AMOUNT OF UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 AND/OR GLIAL FIBRILLARY ACIDIC PROTEIN IN A SAMPLE | Non-Final OA | Abbott Laboratories |
| 18299593 | COMPOSITIONS AND METHODS FOR GENERATING RECOMBINANT ANTIGEN BINDING MOLECULES FROM SINGLE CELLS | Non-Final OA | 10x Genomics, Inc. |
| 18281113 | DIAGNOSIS OF HEMOGLOBINOPATHIES VIA CELL MAGNETIC PROPERTIES | Non-Final OA | Ohio State Innovation Foundation |
| 18669957 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 18709250 | DETECTION METHOD AND DETECTION REAGENT | Non-Final OA | SEKISUI MEDICAL CO., LTD. |
| 18317288 | CHROMOPHORIC POLYMER DOTS WITH NARROW-BAND EMISSION | Non-Final OA | University of Washington through its Center for Commercialization |
| 17762180 | PHOTOPROXIMITY PROFILING OF PROTEIN-PROTEIN INTERACTIONS IN CELLS | Non-Final OA | The University of Chicago |
| 18635442 | PERICELLULAR OXYGEN-CONTROLLING CELL CULTURE INCUBATOR | Non-Final OA | Northeastern University |
| 17781202 | LUMINESCENT ZWITTERIONIC POLYMERIC NANOPARTICLES | Non-Final OA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 18686146 | CONTAMINATION-FREE METAGENOMIC DNA SEQUENCING | Non-Final OA | CORNELL UNIVERSITY |
| 17199228 | SAMPLE DEPLETION AND ENRICHMENT TO IMPROVE THE QUALITY OF DIAGNOSTIC TEST RESULTS | Non-Final OA | VERAVAS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy